Ipamorelin vs Sermorelin: Differences and Which Is Better

Sermorelin and ipamorelin both raise growth hormone, but through different receptors. Sermorelin is the first 29 amino acids of growth hormone releasing hormone (GHRH). As Geref it was FDA-approved in 1990 as a pituitary test and in 1997 for children with growth hormone deficiency, and its label gives a half-life of 11 to 12 minutes. Ipamorelin is a five amino acid peptide acting at a ghrelin-type receptor, with no approved product, a terminal half-life of about 2 hours in healthy men, and one patient trial we could find (114 surgical patients, given intravenously). No trial has compared the two, so neither can honestly be called better.

Updated 1 November 2026. Research information only, not medical advice.

Looking for sleep or skin rather than a head-to-head? The best peptides for sleep and the best peptides for skin and hair compare the wider options.

What Is the Difference Between Sermorelin and Ipamorelin?

Sermorelin works at the GHRH end of the system. The Geref label describes it as an amidated synthetic 29 amino acid peptide corresponding to the amino-terminal segment of native human GHRH, which has 44 residues. Ipamorelin works through the other pathway. In the 1998 paper that introduced it, Raun and colleagues described a pentapeptide that releases GH through a GHRP-like receptor, as shown with GHRP and GHRH antagonists.

The selectivity claim is the reason ipamorelin is called the cleanest GHRP. In the same paper, GHRP-6 and GHRP-2 raised ACTH and cortisol in conscious pigs while ipamorelin did not, even at doses more than 200 times its GH ED50. That is animal data. The duration difference is clearer: sermorelin is gone within minutes, while in healthy men given a 15 minute infusion ipamorelin's GH response peaked at about 40 minutes and its terminal half-life was about 2 hours.

Sermorelin vs Ipamorelin Compared

Which Is Better, Ipamorelin or Sermorelin?

There is no head-to-head trial. A Europe PMC search on 1 November 2026 for papers naming both peptides turned up reviews, preprints and animal work, and no human study comparing them. So "better" depends on the question being asked:

• Regulatory and human record: sermorelin. It was FDA-approved twice, and its label rests on trials in children. Ipamorelin was never approved.
• Half-life and receptor route: ipamorelin lasts longer (about 2 hours against 11 to 12 minutes) and uses the ghrelin-type route. Its one patient trial, in bowel surgery, showed no significant efficacy difference from placebo.
• Lean mass, sleep and skin: neither has been tested against the other. The older version of this page quoted pounds of lean mass and sleep effects with no trial behind them, so those figures are gone. The adult sermorelin data that exists is small and mixed, as the table below shows.

In research-community discussion, ipamorelin is the one people add to a GHRH peptide, and sermorelin is the one chosen for its clinical history. That is reported practice, not a recommendation.

What Human Studies Have Actually Found

Two things stand out. The sermorelin adult trials are tiny: one found no change in IGF-I or body composition over 6 weeks, and the 16 week study used an analogue, not sermorelin. And ipamorelin has no trial in healthy adults at all. The long-acting partner often paired with it, CJC-1295, has its own small trials, covered in the CJC-1295 and ipamorelin stack guide.

Sermorelin and Ipamorelin Together

No published trial gave sermorelin and ipamorelin together. What exists is the older finding that a GHRH and a GHRP act synergistically. Veldhuis and Bowers infused GHRH with GHRP-2, a different ghrelin-receptor peptide, in 47 healthy men aged 18 to 74, and the synergy fell with age and with abdominal visceral fat (both P < 0.001). It supports the idea, not the specific pairing.

In practice the pairing discussed most is CJC-1295 plus ipamorelin, not sermorelin plus ipamorelin. CJC-1295's half-life was estimated at 5.8 to 8.1 days in healthy adults (Teichman 2006), against 11 to 12 minutes for sermorelin, which is the usual reason it is swapped in. Neither pairing is a labelled use.

For the syringe arithmetic, the sermorelin dosage calculator turns vial strength, water volume and dose into units. We do not list doses here; the sermorelin dosage guide and the ipamorelin dosage page set out what labels and studies used.

Side Effects

The numbers come from different people, so they cannot be lined up. The Geref trials in children recorded injection site reactions in about 1 patient in 6, with every other treatment-related effect under 1 percent. The ipamorelin bowel surgery trial recorded any adverse event in 87.5 percent on ipamorelin and 94.8 percent on placebo, in people recovering from an operation. The full breakdowns, kept apart from anecdote, are in sermorelin side effects and ipamorelin side effects.

Legal Status and Cost

Sermorelin's two Geref approvals were withdrawn effective 18 June 2009, and FDA's 2013 notice said the products were not withdrawn for reasons of safety or effectiveness. FDA's page of bulk drug substances that may present significant safety risks (current as of 22 April 2026) lists ipamorelin acetate in Category 2 for outsourcing facilities and does not mention sermorelin. HHS's enforcement discretion notice for 503A compounding, scheduled for the Federal Register on 30 October 2026, is described as a draft; a law firm summary lists six peptides under it (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c), and neither sermorelin nor ipamorelin is among them. The wider picture is in the FDA advisory committee peptide vote write-up.

On the Bureau's vendor price check of 1 November 2026, single-vial listings in stock ran from about $4.20 to $14.00 per mg for ipamorelin (9 stores) and about $6.00 to $15.00 per mg for sermorelin (7 stores), with multi-vial packs excluded. Price per mg is not price per dose, and these are research-market list prices. Vendors the Bureau tracks include Apollo Peptide Sciences, Pantheon Peptides, Amino Club and Ascension Peptides. Stock changes, so compare current prices on best place to buy ipamorelin and best place to buy sermorelin.

Key Takeaways

• Sermorelin is a GHRH fragment with an 11 to 12 minute half-life; ipamorelin is a ghrelin-receptor peptide with about 2 hours
• Sermorelin has an FDA approval history (Geref, withdrawn 2009 for non-safety reasons); ipamorelin has never been approved
• No trial compares them, and none gives them together
• Ipamorelin's one patient trial found no significant efficacy difference from placebo
• The adult GHRH trials are small and mixed, with no body composition change in the sermorelin-fragment trial
• Check the date on any price: stock and prices move

Frequently Asked Questions

What is the difference between sermorelin and ipamorelin?

Sermorelin is the first 29 amino acids of growth hormone releasing hormone (GHRH), with an 11 to 12 minute half-life on its Geref label. Ipamorelin is a five amino acid peptide that acts through a ghrelin-type receptor and has a terminal half-life of about 2 hours in healthy men. Sermorelin was FDA-approved and later discontinued by its maker; ipamorelin has never been approved.

Which is better, ipamorelin or sermorelin?

No trial has compared them, so neither can be called better. Sermorelin has the longer regulatory and paediatric record. Ipamorelin has a longer half-life and animal data showing it does not raise ACTH or cortisol, but its main patient trial, 114 bowel surgery patients, found no significant difference from placebo on its efficacy measures.

Can you use sermorelin and ipamorelin together?

We found no published trial that gave the two together. In 47 healthy men, a GHRH infused with GHRP-2, a different ghrelin-receptor peptide, produced a synergistic growth hormone response that fell with age and abdominal fat. Combination use of this kind is community practice, not something a label or trial supports.

How long does each one last in the body?

The Geref label gives sermorelin a half-life of 11 to 12 minutes after intravenous or subcutaneous doses. In eight healthy men per dose, ipamorelin had a terminal half-life of about 2 hours after a 15 minute infusion, and its growth hormone response peaked at about 0.67 hours.

Is sermorelin or ipamorelin FDA approved?

Sermorelin was approved as Geref in December 1990 for pituitary testing and in September 1997 for children with growth hormone deficiency. Its maker discontinued both in 2008, approval was withdrawn effective 18 June 2009, and FDA found this was not for safety or effectiveness reasons. Ipamorelin has never been approved, and FDA lists it in Category 2 for outsourcing facilities.

Do sermorelin and ipamorelin have the same side effects?

Not in the data we have. In the Geref trials in children, about 1 patient in 6 had an injection site reaction and other effects were each under 1 percent. In the ipamorelin bowel surgery trial, any adverse event occurred in 87.5 percent on ipamorelin and 94.8 percent on placebo, in patients recovering from surgery. Neither set of numbers describes healthy adults.

Is ipamorelin cheaper than sermorelin?

On the Bureau's vendor price check of 1 November 2026, single-vial ipamorelin listings in stock ran from about $4.20 to $14.00 per mg and sermorelin from about $6.00 to $15.00 per mg. Price per mg is not price per dose, and these are research-market list prices, not recommendations.

Sources (checked 1 November 2026)

1. Geref (sermorelin acetate) prescribing information, as reproduced by RxList (the FDA does not host the original label). rxlist.com. Checked 1 November 2026.
2. FDA, Drugs@FDA, NDA 019863 (Geref, sermorelin acetate). accessdata.fda.gov. Checked 1 November 2026.
3. Federal Register, determination that GEREF (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness, 4 March 2013. govinfo.gov. Checked 1 November 2026.
4. FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). fda.gov. Checked 1 November 2026.
5. HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192, scheduled for publication 30 October 2026. federalregister.gov. Text read 1 November 2026.
6. BakerHostetler, HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (secondary summary of the six-peptide list; HHS's own appendix would not load). bakerlaw.com. Checked 1 November 2026.
7. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998. PMID 9849822. Checked 1 November 2026.
8. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res, 1999. PMID 10496658. Abstract read on Europe PMC, checked 1 November 2026.
9. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis, 2014. PMID 25331030. Checked 1 November 2026.
10. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 1997. PMID 9005976. Checked 1 November 2026.
11. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab, 1997. PMID 9141536. Abstract read on Europe PMC, checked 1 November 2026.
12. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab, 2009. PMID 19240251. Checked 1 November 2026.
13. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006. PMID 16352683. Abstract read on Europe PMC, checked 1 November 2026.
14. Europe PMC search for papers naming both sermorelin and ipamorelin (no head-to-head human study found). europepmc.org. Checked 1 November 2026.
15. Peptide Bureau Vendor Watch price data, read 1 November 2026 (single-vial in-stock listings, multi-vial packs excluded).